Home      About this journal      Authors      Editors      Readers      Archive      Contact us
Systematic review and re-evaluation of Wumei Pill and modified prescription in the treatment of colorectal diseases
Hits 1231  Download times 621  Received:November 08, 2023  
View Full Text  View/Add Comment  Download reader
DOI   10.11656/j.issn.1672-1519.2024.02.11
Key Words   Wumei Pill;colorectal disease;systematic review and re-evalnation;AMSTAR 2;PRISMA 2020;GRADE
Author NameAffiliationE-mail
ZHANG Jie Shaanxi University of Chinese Medicine, Xianyang 712046, China  
YANG Qingrui Shaanxi University of Chinese Medicine, Xianyang 712046, China  
LEI Yuyu Shaanxi University of Chinese Medicine, Xianyang 712046, China  
CHEN Huan Shaanxi University of Chinese Medicine, Xianyang 712046, China  
LI Cailing Shaanxi University of Chinese Medicine, Xianyang 712046, China  
LI Cui Shaanxi University of Chinese Medicine, Xianyang 712046, China  
DU Xiaoquan Second Department of Digestion, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, China duxiaoquan1997@163.com 
Abstract
    [Objective] To overview the systematic reviews(SRs) of Wumei Pill and modified prescription in treating colorectal diseases,and provide evidence-based medical basis for clinic. [Methods] PubMed,Cochrane Library,Embase,CNKI,VIP,WanFang Data and CBM databases were searched to collect SRs of Wumei Pill and modified prescription for colorectal diseases from inception to December 31st,2022. Two reviewers independently screened literatures and extracted data. Then,AMSTAR 2,PRISMA 2020 and GRADE were used to assess the methodological quality,report quality and evidence quality of the included studies. The results of overview were analyzed in a comprehensive manner. [Results] A total of 12 SRs were included,involving 4 diseases,including ulcerative colitis(UC),irritable bowel syndrome(IBS),diarrhea and postoperative colorectal adenomatous polyps. And according to the AMSTAR 2 evaluation results,10 SRs were of low quality,and 2 SRs were of extremely low quality. PRISMA 2020 scores ranged from 19.5 to 30,of which 6 SRs were of medium quality and 6 SRs were of low quality. A total of 51 outcome indicators were reported by SRs,and the GRADE evaluation results showed that there were 30 medium quality,19 low quality and 2 extremely low quality. According to available evidence,as compared with routine treatment,no-treatment control or placebo,Wumei Pill and modified prescription or combined with routine treatment have better curative effect on UC,IBS,diarrhea and postoperative colorectal adenomatous polyps. [Conclusion] Wumei Pill and modified prescription have a good curative effect on colorectal diseases. As the methodological quality,report quality and evidence quality of the included studies are relatively low,this conclusion should be treated with caution and be confirmed by more high-quality studies in the future.

You are the Guest visitor.

Copyright @ 2007
Address: 10 Boyanghu Road, West District of Tuanbo New City, Jinghai District, Tianjin 301617, China  Postcode:
Tel:  Fax:  E-mail:
Beijing E-Tiller Co., Ltd.